8[5]Moses R,Slobodniuk R,Boyages S,et al.Additional treatment with repaglinide provides significant improvement in glycemic controling NIDDM patients poorly controlled on metformin[C].57th Scientific Sessions of the American Dabetes Association,Boston,MA,USA,1997.
9[6]Moses r,Slobodniuk R,Boyages S,et al.Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes[J].DiabetesCare,1999,22:1192124.
3Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes meUitus[J]. Mayo Clin Proc, 2010, 85(12 Suppl): S5-S14.
4Liao EP. Management of type 2 diabetes: new and future developments in treatment[J]. Am J Med, 2012, 125(10): S2-S3.
5Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090- 1101.
6Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians[J]. Ann Intern Med, 2012, 156 (3): 218-231.
7Drucker DJ, Nauck MA.The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inbibitors in type 2 diabetes[J]. Lancet, 2006, 368(9548): 1696-1705.
8Gallwitz B, Guzman J, Dotta F, et aL Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure(EUREXA): an open- label, randomised controlled trial[J]. Lancet, 2012, 379(9833): 2270-2278.
9Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatifis in type 2 diabetes mellitus: a population-based matched case- control study[J]. JAMA Intern Med, 2013, 173(7): 534-539.
